PureTech Health Announces FY 2025 Results, Strategic Refinement, and Intent to Delist from Nasdaq

PureTech Health reported its full-year 2025 financial results and provided a strategic update focused on its "hub-and-spoke" model. The company ended 2025 with $277.1 million in level cash and short-term investments, providing an operational runway through at least 2028. Key clinical highlights include the Phase 3 readiness of deupirfenidone for idiopathic pulmonary fibrosis (IPF) via its entity Celea Therapeutics, which has substantially completed a financing round targeted to close in Q3 2026. Gallop Oncology reported positive Phase 1b data for LYT-200 in myeloid malignancies and plans to seek external capital for a registration-enabling trial in 2027. Seaport Therapeutics filed a registration statement for a potential IPO and reported positive Phase 1 data for GlyphAgo. PureTech also announced its intention to voluntarily delist its ADSs from Nasdaq to consolidate trading on the London Stock Exchange, aiming to reduce administrative costs and simplify its corporate structure. The company plans to return an increased proportion of future cash generation to shareholders as it transitions toward a leaner operating model.